Teva Pharmaceutical Industries (TEVA) Advances TEV 408, Is The Stock Still Cheap?
Why TEV-408 Matters for Teva Pharmaceutical Industries Stock
Teva Pharmaceutical Industries (NYSE:TEVA) has become a focus after the company said its investigational anti IL 15 antibody, TEV 408, will move into a Phase 2b vitiligo trial following encouraging Phase 1b data.
For investors, this update puts Teva’s biopharma pipeline in the spotlight, since TEV 408 is being studied not only in vitiligo but also in celiac disease, where it already has U.S. FDA Fast Track status.
See our latest analysis for Teva Pharmaceutical Industries.
Teva Pharmaceutical Industries shares now trade at US$31.82. Despite a recent period of weaker momentum, with the 7 day share price return down 8.17% and the 30 day share price return down 8.11%, the longer term picture remains strong. The 1 year total shareholder return stands at 98.38% and the 3 year total shareholder return is more than 3x, as investors weigh the TEV 408 update alongside progress in higher value biopharma and its mixed valuation signals.
If you are looking beyond Teva to other potential ideas in healthcare, this could be a good moment to review companies in a similar space using our healthcare focused screener of 40 healthcare AI stocks
After a sharp run over three years and a recent pullback, Teva Pharmaceutical Industries now sits at a price that some models flag as discounted, while earnings multiples look less generous. So does the current balance of risk and reward still lean your way?
Most Popular Narrative: 22.2% Undervalued
The most followed narrative on Teva Pharmaceutical Industries currently points to a fair value of $40.90 versus the last close at $31.82, framing TEV 408 within a wider earnings and margin story.
Teva's strategic focus and rapid execution on expanding its branded products (AUSTEDO, AJOVY, UZEDY, and upcoming olanzapine LAI), combined with a robust late stage pipeline targeting large patient populations, are expected to drive higher margin topline growth and a more profitable product mix, supporting gross margin and net earnings expansion.
Want to see what growth path and margin reset sits behind that fair value for Teva Pharmaceutical Industries? The narrative leans on modest revenue expansion, a sharper profit ramp and a future earnings multiple that assumes investors stay willing to pay up for that mix shift.
Result: Fair Value of $40.90 (UNDERVALUED)
Have a read of the narrative in full and understand what's behind the forecasts.
However, Teva Pharmaceutical Industries still faces clear risks, including its heavy reliance on a few branded drugs and a sizeable net debt position that could constrain flexibility.
Find out about the key risks to this Teva Pharmaceutical Industries narrative.
Next Steps
With both risks and rewards in play for Teva Pharmaceutical Industries, this is a good time to review the data yourself and move quickly to shape your own view by weighing the 4 key rewards and 2 important warning signs
Looking for more investment ideas beyond Teva Pharmaceutical Industries?
Teva Pharmaceutical Industries may sit at the center of your watchlist today, but you could miss useful opportunities if you stop your research with a single stock.
- Target resilient cash generators with strong upside potential by scanning companies in the 44 high quality undervalued stocks that also show healthy fundamentals.
- Prioritise steady income by reviewing companies in the 8 dividend fortresses that focus on higher yielding payouts with an emphasis on durability.
- Reduce portfolio stress by concentrating on businesses in the 79 resilient stocks with low risk scores that pair measured risk scores with dependable financial profiles.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com